Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alexion Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Alexion Pharmaceuticals fell $2.20 (-2.0%) to $107.56 on heavy volume. Throughout the day, 2,629,472 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,584,700 shares. The stock ranged in price between $105.32-$110.88 after having opened the day at $107.87 as compared to the previous trading day's close of $109.76. Other companies within the Drugs industry that declined today were:




), down 29.6%,

AEterna Zentaris



), down 20.9%,

OncoMed Pharmaceuticals



), down 14.2% and

IntelliPharmaCeutics International



), down 13.0%.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $21.4 billion and is part of the health care sector. Shares are up 16.7% year to date as of the close of trading on Wednesday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Alexion Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front,




), up 15.2%,

Sangamo BioSciences



), up 11.6%,

Prosensa Holding N.V



), up 9.0% and




), up 7.8% , were all gainers within the drugs industry with

Celgene Corporation



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.